What Is Gene Patch Technology And How Could It Potentially Stop Disease And Other Ailments

Presenter: Neal Howard
Guest: Dr. Stephen Shrewsbury
Guest Bio: Dr. Shrewsbury was most recently Senior Vice President, Preclinical & Clinical Development and Chief Medical Officer of AVI BioPharma (now Sarepta Therapeutics). From 2005 until 2009, he held similar roles at Adamas Pharmaceuticals and MAP Pharmaceuticals. While at MAP, Dr. Shrewsbury lead four inhaled drug programs and took two lead candidates (in asthma and migraine) from preclinical stage to Phase III in 18 months. Prior to his experience in biotechnology, Dr. Shrewsbury spent 10 years with Glaxo and Chiron launching notable respiratory programs such as Seretide in Europe and Flovent and Advair in the US. Dr. Shrewsbury received his medical degree from the University of Liverpool, UK and spent 13 years working in the UK National Health Service before entering the pharmaceutical industry.

Segment Overview
Dr. Stephen Shrewsbury discusses “gene patch” technology and how it could potentially stop disease and other ailments.

Transcription

Health Professional Radio

Neal Howard: Hello. You’re listening to Health Professional Radio. I’m your host, Neal Howard. Thank you so much for being with us today. What if medical science could protect us from biological weapons? We hear a lot about the War on Terrorism and things of that nature. What if medical science could stop, say, cancer or many other diseases dead in their tracks? What if medical science could do this?

Our guest in studio today is Dr. Steven Shrewsbury. He has been doing extensive research in what’s known as gene patches. He’s also an author as well as a researcher. He’s the author of Defy Your DNA. How are you doing this morning, doctor?

Want to continue reading? Please log-in or register to see the Full Transcript.